Quarterly ResultMay 7, 2026, 04:20 PM
Caribou Q1 Net Loss $(25.1)M; FDA Aligns on vispa-cel Pivotal Trial
AI Summary
Caribou Biosciences reported a net loss of $(25.1) million for Q1 2026, an improvement from $(40.0) million in Q1 2025, with R&D and G&A expenses decreasing due to strategic pipeline prioritization and workforce reduction. The company announced alignment with the FDA on the pivotal ANTLER-3 trial design for vispa-cel in second-line large B cell lymphoma. Additionally, the FDA granted RMAT designation to CB-011 for relapsed or refractory multiple myeloma, with further clinical data updates for both programs expected in 2026.
Key Highlights
- Aligned with FDA on pivotal ANTLER-3 trial design for vispa-cel in 2L LBCL.
- CB-011 granted RMAT designation by FDA for relapsed or refractory multiple myeloma.
- Q1 2026 net loss improved to $(25.1) million from $(40.0) million YoY.
- Research and development expenses decreased to $20.6 million from $35.5 million in Q1 2025.
- General and administrative expenses decreased to $8.1 million from $9.7 million in Q1 2025.
- Cash, cash equivalents, and marketable securities totaled $118.6 million as of March 31, 2026.
- Cash runway expected into 2H 2027, with funding sought for vispa-cel pivotal trial.
- Longer follow-up data for vispa-cel and CB-011 clinical trials expected in 2026.